NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-386 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. This FOA will use the NIH Research Project Grant (R01) award mechanism and runs in parallel with another FOA, PAR-20-NNN, which encourages applications under the R21 mechanism.
Funding Opportunity RFA-DK-19-505 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the web portal and underlying, curated knowledge base; as well as to become the flagship resource encompassing the myriad types of data and information that provides an understanding of the biological heterogeneity in patients with T2D and its complications. In its next five-year period, the AMP T2D KP will be expected to expand the KPs data sets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base. To support the conduct of these studies, the AMP T2D KP will coordinate, support, and work with companion Functional Genomic Project awardees (RFA-DK-19-012) to form a Consortium. The AMP T2D KP will also oversee an opportunity pool of funds to solicit collaborative projects to accomplish the objectives of the Consortium.
Funding Opportunity RFA-DK-19-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for large-scale complex multi-disciplinary Functional Genomics Projects (FGPs) to determine the contributions and mechanisms underlying the contribution of risk-associated variants and their downstream effector transcripts for type 2 diabetes (T2D). The intent is to generate knowledge and tools to enable the identification of putative biomarkers and therapeutic targets by future efforts. Genome-wide association studies (GWAS) and other genomic studies of T2D and its complications have found many variants that are statistically associated with disease risk, disease protection, progression to complications, or other traits. However, such studies do not show which variants in genomic elements cause these effects or how they result in differences in function. Applications submitted to this RFA will systematically identify causal variants and effector transcripts associated with all known T2D risk variants, verify the role of downstream effector transcripts, build network models that explain their role(s) in T2D and its complications, and identify key readouts and modulation points in these networks. Data, tools, and reagents generated by these projects will be released rapidly to facilitate more in-depth study by the broad scientific community. Awardees to this solicitation will form a Consortium with the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal awardee (AMP T2D KP; RFA-DK-19-505) to accomplish collective goals.
Funding Opportunity RFA-AG-20-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to pursue validation studies of cognitive screening instruments or assessments in clinical settings and to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA requires prior preliminary data gathered during the development of cognitive screening tools and/or assessments. This FOA will also support research to validate these tools as well as their implementation in large clinical settings. Plans for validation of cognitive impairment against relevant Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) biomarkers are encouraged but not required.
Funding Opportunity RFA-AG-20-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to pursue development and validation studies of cognitive screening instruments or assessments in clinical settings and to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA will support an R61 pilot phase (Stage I) which will allow researchers to develop and validate tools for cognitive assessment and then create scalable, tailored interventions for patients experiencing cognitive decline to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase (Stage IV) for implementation of pragmatic trials. All applicants are required to address health disparities. This FOA does not require preliminary data.
Funding Opportunity RFA-OD-19-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on at the influence and intersection of sex and gender in health and disease including: (1) research proposals that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five research priorities in the new 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered through by NIH ICs using funds that have been made available through the Office of Research on Womens Health (ORWH) and the scientific partnering Institutes and Centers across NIH.
Notice NOT-TR-19-028 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-029 from the NIH Guide for Grants and Contracts
Notice NOT-MD-20-003 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-036 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-011 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-010 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-077 from the NIH Guide for Grants and Contracts
Notice NOT-MD-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-DE-19-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-140 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-19-504 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-19-009 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).
Funding Opportunity RFA-DK-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-19-504 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.
Funding Opportunity RFA-DA-20-027 from the NIH Guide for Grants and Contracts. To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community.
Notice NOT-DK-19-019 from the NIH Guide for Grants and Contracts